Key clinical point: In a real-world setting, secukinumab demonstrated substantial efficacy in improving disease activity scores, enthesitis, and dactylitis in patients with psoriatic arthritis (PsA).
Major finding: The proportion of patients who achieved low disease activity according to the Disease Activity Score-28 C-reactive protein measurements increased significantly from 25% at baseline to 66% after 6 months ( P < .001), with the improvements maintained for up to 24 months (75%). After 6 months of secukinumab treatment, complete resolution of enthesitis and dactylitis was reported by the majority of patients (82% and 67%, respectively) along with an improvement in pain scores.
Study details: Findings are from an observational retrospective study including 178 patients with PsA who received secukinumab in the first-, second-, or third- or higher line setting.
Disclosures: This study was sponsored by Novartis Farmacéutica, S.A. Two authors declared financial and non-financial ties with various sources including Novartis. Other authors declared no conflicts of interest.
Source: Alegre-Sancho JJ et al . Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis. Front Med (Lausanne). 2023;10:1294247 (Nov 20). doi: 10.3389/fmed.2023.1294247